About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Patients who need enteral nutrition may also require PPIs for acid suppression. The currently available and most widely prescribed PPIs are reviewed, along with their routes of delivery in nasogastric, gastrostomy, and jejunal feeding tubes.
Terri M. Wensel, PharmD
Emerging Trends in the Blogosphere
Even pharmaceutical companies, which have long shied away from blogging on the Internet, understand that the conventional static Web site is just not good enough any more. Will future pharma bloggers be able to incorporate the real-time engagement and transparency that are needed?
If approved by the FDA, the platelet inhibitor prasugrel will be a first-in-its-class competitor of clopidogrel (Plavix). The new drug is designed to reduce the risk of nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular disease, but bleeding and the risk of neoplasms can result.
Topics include milnacipran (Savella) tablets for fibromyalgia, calcitriol ointment (Vectical) for plaque psoriasis, and degarelix subcutaneous injection, a hormone for treating advanced prostate cancer.
Marvin M. Goldenberg, PhD, RPh, MS
David B. Nash, MD, MBA, discusses evidence-based case rates, the building blocks of a new payment model that aims to support a patient-centered health environment.
David B. Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, recommends rest periods, off-duty time, naps, meal breaks, and other safety practices to prevent fatigue in health care workers, thereby minimizing the potential for mistakes on the job.
Matthew Grissinger, RPh, FASCP
Stephen Barlas discusses how the FDA under the Obama administration might deal with off-label drug promotion for unapproved uses.
From ATryn to Tindamax, P&T presents the latest information about FDA approvals, indications, recalls, and updates.
Rilonacept (Arcalyst), an Interleukin-1 Trap for the Treatment of Cryopyrin-Associated Periodic Syndromes
Drs. Kapur and Bonk review rilonacept (Arcalyst) for treating cryopyrin-associated periodic syndromes.
Saloni Kapur, PharmD, MPA, and Mary Ellen Bonk, PharmD